We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Metallic Stent Overcomes Uretral Obstructions

By HospiMedica staff writers
Posted on 02 Apr 2007
A metallic uretral stent may allow patients with malignant uretral obstruction to avoid the discomfort and disfigurement associated with placement of a nephrostomy tube. More...


The Resonance metallic uretral stent incorporates a specially designed metallic hollow tube that relieves obstruction in the ureter. With normal drainage, the patient is able to channel toxins produced during chemotherapy without the need for placement of a nephrostomy drainage tube during treatments. The stent has a 12-month indwelling time that allows for normal long-term renal drainage, eliminating the need for numerous and painful stent changes.

Despite the initial higher costs of the metallic stent when compared to plastic stents, the stent's design provides superior compressive and radial strengths, resisting up to 25 times more extrinsic compression than that needed to occlude plastic stents. Additionally, the placement system leads to precise stent placement, and an internal safety wire minimizes risk during placement and removal. As a result, use of the Resonance may dramatically reduce hospital admissions and their associated costs. The Resonance metallic urethral stent is made by Cook Urology, a division of Cook Medical (Bloomington, IN, USA).

"Cook continues to be the innovator across a wide range of urological procedures. The uniquely designed Resonance stent will have a significant, positive impact on the patient's quality of life as a result of the Resonance stent's extended indwelling term,” said Jerry French, senior vice president and global strategic business unit leader for Cook Urology. "No longer will patients need to suffer from the pain and discomfort caused by repeated hospitalizations for stent changes.”

The dramatic rise in gender-specific cancers, such as ovarian and prostate cancer, which often causes extrinsic uretral compression, has led to a more aggressive approach to treatment. This in turn has led to an increased awareness of the need for uretral drainage during chemotherapy-based cancer treatment.


Related Links:
Cook Medical

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.